Jubilant Biosys Limited is a Contract Research and Manufacturing Organization (CRMO) that provides integrated services from early drug discovery to preclinical studies for global pharmaceutical and biopharmaceutical companies. With bases in India and Europe, we contribute to the creation of innovative therapeutics through high-quality research and development support.
Here, we will introduce in detail Jubilant Biosys Limited strengths in non-clinical studies, examples of disease models they possess, and specific use cases.
One of Jubilant Biosys Limited's features is its ability to address a wide range of disease areas, including cancer, central nervous system disorders, metabolic diseases, pain, and inflammation. At its advanced research facilities in India and France,in vitroandin vivoWe offer a wide range of non-clinical testing services, from pharmacology studies to drug metabolism and pharmacokinetics (DMPK) studies, and GLP and non-GLP toxicology studies, flexibly meeting the diverse drug discovery needs of our customers.
Another key feature is our integrated approach, leveraging comprehensive facilities and advanced expertise. Our experienced team of scientists utilize high-performance infrastructure to deliver high-quality data, supporting rapid decision-making from the early stages of development. We go beyond simple contract testing; as a CRDMO, we offer end-to-end support, from identifying drug discovery targets to preclinical testing and even the scale-up manufacturing of active pharmaceutical ingredients, thereby facilitating a more efficient drug discovery process.
The company offers a wide range of [products/services] to thoroughly evaluate complex disease mechanisms.in vivoI own animal models.
Representative examples include pain models that evaluate chemotherapy-induced allodynia and bone cancer pain, and skin disease models for contact dermatitis and psoriasis. In addition, "metabolic disease models," including diabetes, are well-developed, supporting the efficacy evaluation of new drug candidate compounds with study designs tailored to the characteristics of each disease.
For cancer, a key focus area, we offer a rich selection of proprietary, advanced oncology models. Specifically, evaluation systems utilizing a wide variety of cancer cell lines, including pancreatic, lung, and breast cancer, are available. By leveraging these models, which are based on past research trends, we can meticulously validate the efficacy and mechanisms of action of anticancer drugs, thereby supporting efforts to accelerate and achieve success in the development of innovative pharmaceuticals in the field of oncology.
Due to the nature of being a CRDMO, strict confidentiality agreements (NDAs) are in place, and details of individual drug discovery program support are not publicly disclosed on our website. For approaches to specific disease targets or detailed case studies, please contact us directly to receive information disclosure or proposals tailored to your requirements.
Jubilant Biosys Limited also supports the non-clinical studies of its sister company, Jubilant Therapeutics. The following are case studies featured in Jubilant Therapeutics' public disclosures.
We conducted non-clinical studies on "JBI-778," a novel PRMT5 inhibitor candidate for anti-cancer drugs. This compound isin vitroIn addition to demonstrating antitumor activity in preclinical studies, oral administration achieved greater than 90% tumor growth inhibition in a mouse Z-138 xenograft model%.
Furthermore, sustained exposure and substantial survival extension in the brain have been confirmed in a glioblastoma (GBM) model of the same location, showing promising data as a clinical candidate.
Jubilant Biosys Limited is a global company that seamlessly supports early drug discovery research through to commercial production. Leveraging its infrastructure and expertise, it holistically supports its customers' drug development.
| Address | India (Bengaluru, Noida, Greater Noida), France (Saint-Julien-en-Genevois) |
|---|---|
| Tel | +91 120 436 1000 (Representative of Head Office in India) |
| Website | https://www.jubilantbiosys.com/ |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.